The reduction in TF expression via nuclear factor kappa B (NF-κB) inhibitors promotes the attenuation of alveolar hypercoagulation and fibrinolysis inhibition in experimental models of ARDS [147,148]. Here, NFKB1 is linked to acute respiratory distress syndrome.